Skip to main content
. Author manuscript; available in PMC: 2017 Jul 27.
Published in final edited form as: Cochrane Database Syst Rev. 2017 Jan 27;1:CD011305. doi: 10.1002/14651858.CD011305.pub2

Table 5. Review secondary outcomes - platelet and red cell transfusions.

Study ID Number of PLTs transfused per participant Number of participant-days with PLT transfusions Proportion of participant-days with RBC transfusions Interval between PLT transfusions (mean & SD)(days) Number of PLT units per transfusion (mean & SD) (units) Nmber of PLT transfusion per participant
RCTs
De Zern 2016 NR NR NR NR NR Restrictive:
median:9 (IQR: 5.5 to 12.5)
Liberal;
median: 9 (IQR: 7 to 12)
Robitaille 2013 NR NR NR NR NR NR
Webert 2008 Restrictive:
26/29 from study entry, 26 from when target Hb reached
Liberal:
27/31 from study entry; 26 from when target Hb reached
Restrictive:
124 from study entry; 122 from Hb 80 g/L to 100 g/L
Liberal:
0.265 from study entry; 0.283 from when Hb > 120 g/L
Restrictive:
0.249 from study entry; 0.261 from when Hb 8-10
Liberal:
0.265 from study entry; 0.283 from when Hb > 12 [RR 1.06; 95% CI 0.74 to 1.52] [RR 1.02: 95% CI 0.73 to 1.44; once study Hb threshold reached]a
NR NR NR
NRS
Jansen 2004 Restrictive:
Mean 7.5 (SD 3.8); median 7 (SE 0.6); range 2 to 18
Liberal:
Mean 8.5 (SD 4.9); median 7 (SE 0.7); range 2 to 30 P > 0.05
NR NR Restrictive:
4 days (No SD)
Liberal:
3.8 days (No SD)
Restrictive:
Mean 1.1 (SD 0.4); median 1 (SE 0.03); range 1 to 4
Liberal:
Mean 1.2 (SD 0.5);Median 1 (SE 0.03); range 1 to 4
NR
a

Data analysed by study authors, reported as relative risks derived from Cox regression models.

IQR = Interquartile range